Phenotypes associated with this allele

• Allele Symbol: Col1a1^{tm1(tetO-Tcfap2c)Hsc}
• Allele Name: targeted mutation 1, Hubert Schorle
• Allele ID: MGI:4949113
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Col1a1^tm1(tetO-Tcfap2c)Hsc/Col1a1^+ Gt(ROSA)26Sor^tm1(rtTA*M2)Jae/Gt(ROSA)26Sor^+	involves: 129S4/SvJae * C57BL/6	MGI:5051636

Genotype
MGI:5051636

cx1

• Allelic Composition: Col1a1^{tm1(tetO-Tcfap2c)Hsc}/Col1a1⁺; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Col1a1^{tm1(tetO-Tcfap2c)Hsc}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor⁺ mice show increased proliferation and induced hepatic steatosis

mortality/aging

premature death ( J:174049 )

• within 6 to 7 days of doxycycline treatment

homeostasis/metabolism

abnormal circulating enzyme level ( J:174049 )

• after doxycycline treatment, mice exhibit increased serum levels of aspartate transaminase, alanine transaminase, alkaline phosphatase, lipase, amylase, lactate dehydrogenase levels compared with control mice

increased circulating alanine transaminase level ( J:174049 )

• after doxycycline treatment

increased circulating alkaline phosphatase level ( J:174049 )

• after doxycycline treatment

increased circulating amylase level ( J:174049 )

• after doxycycline treatment

increased circulating aspartate transaminase level ( J:174049 )

• after doxycycline treatment

increased circulating lactate dehydrogenase level ( J:174049 )

• after doxycycline treatment

dehydration ( J:174049 )

• after doxycycline treatment

decreased liver glycogen level ( J:174049 )

• after doxycycline treatment

liver/biliary system

increased hepatocyte apoptosis ( J:174049 )

• after doxycycline treatment

increased hepatocyte proliferation ( J:174049 )

• after doxycycline treatment

decreased liver glycogen level ( J:174049 )

• after doxycycline treatment

abnormal hepatocyte morphology ( J:174049 )

• after doxycycline treatment, hepatocytes exhibit abnormally bright mitochondria and increased mitophagy compared to in cells from control mice

abnormal hepatocyte mitochondrial morphology ( J:174049 )

• after doxycycline treatment, hepatocytes exhibit abnormally bright mitochondria

microvesicular hepatic steatosis ( J:174049 )

• after doxycycline treatment, mice exhibit microvesicular steatosis unlike control mice

liver failure ( J:174049 )

• after doxycycline treatment

digestive/alimentary system

abnormal enterocyte proliferation ( J:174049 )

• after doxycycline treatment, the proliferative zone is expanded to cover crypt and villus compared to in control mice

abnormal intestine development ( J:174049 )

• after doxycycline treatment, the number of terminally differentiated intestinal cells (absorptive enterocytes, goblet cells, Paneth, cells and enteroendocrine cells) is reduced compared to in control mice

abnormal intestinal mucosa morphology ( J:174049 )

• after doxycycline treatment

abnormal small intestine morphology ( J:174049 )

• after doxycycline treatment, the ratio of crypt length to villus length in the duodenum, jejunum, and ileum is increased compared to in control mice

endocrine/exocrine glands

abnormal pancreas physiology ( J:174049 )

• after doxycycline treatment, mice exhibit pancreatic injury unlike control mice

behavior/neurological

lethargy ( J:174049 )

• after doxycycline treatment

growth/size/body

weight loss ( J:174049 )

• after doxycycline treatment

immune system

immune system phenotype ( J:174049 )

N • doxycycline-treated mice do not exhibit induction of inflammatory processes

cellular

abnormal hepatocyte mitochondrial morphology ( J:174049 )

• after doxycycline treatment, hepatocytes exhibit abnormally bright mitochondria

increased hepatocyte apoptosis ( J:174049 )

• after doxycycline treatment

abnormal enterocyte proliferation ( J:174049 )

• after doxycycline treatment, the proliferative zone is expanded to cover crypt and villus compared to in control mice

increased hepatocyte proliferation ( J:174049 )

• after doxycycline treatment